Article
Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.
Science (New York, N.Y.) - 7 Aug 2025
Pizzo Michelle E, Plowey Edward D, Khoury Nathalie, Kwan Wanda, Abettan Jordan, DeVos Sarah L, Discenza Claire B, Earr Timothy, Joy David, Lye-Barthel Ming, Roche Elysia, Chan Darren, Dugas Jason C, Gadkar Kapil, Hamann Stefan, Meisner René, Sebalusky Jennifer, Silva Amaral Ana Claudia, Becerra Isabel, Chau Roni, Chow Johann, Clemens Allisa J, Dennis Mark S, Duque Joseph, Fusaro Laura, Getz Jennifer A, Kariolis Mihalis S, Kim Do Jin, Lechtenberg Kendra J, Leung Amy Wing-Sze, Moshkforoush Arash, Nguyen Hoang N, Ojo Emmanuel S, Thomsen Elliot R, Torres Vanessa O, Sanchez Pascal E, Shan Lu, Silverman Adam P, Sweeney Zachary K, Solanoy Hilda, Tong Raymond, Calvert Meredith E, Watts Ryan J, Thorne Robert G, Weinreb Paul H, Walsh Dominic M, Lewcock Joseph W, Bussiere Thierry, Zuchero Y Joy Yu
Abstract excerpt
Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the brain, are a major safety concern in patients with Alzheimer's disease. We developed an antibody transport vehicle (ATV) targeting transferrin receptor (TfR) for brain delivery of anti-amyloid-β protein (anti-Aβ) using asymmetrical Fc mutations (ATVcisLALA) that mitigates TfR-related...
Read the complete abstract on PubMedTopics
- Receptors, Transferrin